391 related articles for article (PubMed ID: 23738667)
1. Therapeutic nanomedicine for brain cancer.
Tzeng SY; Green JJ
Ther Deliv; 2013 Jun; 4(6):687-704. PubMed ID: 23738667
[TBL] [Abstract][Full Text] [Related]
2. Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo.
Mangraviti A; Tzeng SY; Kozielski KL; Wang Y; Jin Y; Gullotti D; Pedone M; Buaron N; Liu A; Wilson DR; Hansen SK; Rodriguez FJ; Gao GD; DiMeco F; Brem H; Olivi A; Tyler B; Green JJ
ACS Nano; 2015 Feb; 9(2):1236-49. PubMed ID: 25643235
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours.
Ferraris C; Cavalli R; Panciani PP; Battaglia L
Int J Nanomedicine; 2020; 15():2999-3022. PubMed ID: 32431498
[TBL] [Abstract][Full Text] [Related]
4. Novel Nanotechnologies for Brain Cancer Therapeutics and Imaging.
Ferroni L; Gardin C; Della Puppa A; Sivolella S; Brunello G; Scienza R; Bressan E; D'Avella D; Zavan B
J Biomed Nanotechnol; 2015 Nov; 11(11):1899-912. PubMed ID: 26554151
[TBL] [Abstract][Full Text] [Related]
5. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.
Kuang Y; An S; Guo Y; Huang S; Shao K; Liu Y; Li J; Ma H; Jiang C
Int J Pharm; 2013 Sep; 454(1):11-20. PubMed ID: 23867728
[TBL] [Abstract][Full Text] [Related]
6. Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.
Chaichana KL; Pinheiro L; Brem H
Ther Deliv; 2015 Mar; 6(3):353-69. PubMed ID: 25853310
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
Brighi C; Reid L; Genovesi LA; Kojic M; Millar A; Bruce Z; White AL; Day BW; Rose S; Whittaker AK; Puttick S
Theranostics; 2020; 10(14):6361-6371. PubMed ID: 32483457
[TBL] [Abstract][Full Text] [Related]
8. Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.
Nafee N; Gouda N
Curr Gene Ther; 2017; 17(2):154-169. PubMed ID: 28494740
[TBL] [Abstract][Full Text] [Related]
9. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
10. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
11. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
12. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor.
Garg T; Bhandari S; Rath G; Goyal AK
J Drug Target; 2015 Dec; 23(10):865-87. PubMed ID: 25835469
[TBL] [Abstract][Full Text] [Related]
13. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Miller-Kleinhenz JM; Bozeman EN; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
15. Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption.
Janowicz PW; Houston ZH; Bunt J; Fletcher NL; Bell CA; Cowin G; Howard CB; Taslima D; Westra van Holthe N; Prior A; Soh V; Ghosh S; Humphries J; Huda P; Mahler SM; Richards LJ; Thurecht KJ
Biomaterials; 2022 Apr; 283():121416. PubMed ID: 35217483
[TBL] [Abstract][Full Text] [Related]
16. Targeted brain delivery nanoparticles for malignant gliomas.
Pinto MP; Arce M; Yameen B; Vilos C
Nanomedicine (Lond); 2017 Jan; 12(1):59-72. PubMed ID: 27876436
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine.
Sharma HS; Muresanu DF; Castellani RJ; Nozari A; Lafuente JV; Tian ZR; Sahib S; Bryukhovetskiy I; Bryukhovetskiy A; Buzoianu AD; Patnaik R; Wiklund L; Sharma A
Int Rev Neurobiol; 2020; 151():1-66. PubMed ID: 32448602
[TBL] [Abstract][Full Text] [Related]
18. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
Ganipineni LP; Danhier F; Préat V
J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
[TBL] [Abstract][Full Text] [Related]
19. Gene Therapy Based on Lipid Nanoparticles as Non-viral Vectors for Glioma Treatment.
Luiz MT; Tofani LB; Araújo VHS; Di Filippo LD; Duarte JL; Marchetti JM; Chorilli M
Curr Gene Ther; 2021; 21(5):452-463. PubMed ID: 33390137
[TBL] [Abstract][Full Text] [Related]
20. Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments.
Mamun AA; Uddin MS; Perveen A; Jha NK; Alghamdi BS; Jeandet P; Zhang HJ; Ashraf GM
Semin Cancer Biol; 2022 Nov; 86(Pt 2):101-116. PubMed ID: 36084815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
